Tilray Inc. (NASDAQ: TLRY) is slated to report third quarter 2019 earnings results on Tuesday, November 12, after the market closes. Analysts expect the company to report a loss of $0.30 per share on revenue of $49.5 million. This compares to a loss of $0.20 per share on revenue of $10.05 million reported a year earlier.
The company’s topline results are likely to benefit from the Manitoba Harvest acquisition, the legalization of the Canadian adult-use market and growth in Europe as the momentum from last quarter is likely to continue into the third quarter.
During the quarter, Tilray announced the acquisition of cannabis retail operator 420 Investments Ltd. This deal is expected to help Tilray expand into other Canadian provincial markets. The transaction is expected to close by the end of the first quarter of 2020.
Last month, the company imported medical cannabis into the US from Canada in support of a new clinical trial that will test the efficacy of medical cannabis in treating breast cancer. Updates on these topics are worth watching.
Also read: Tilray Q2 2019 Earnings Conference Call Transcript
The company’s bottom line results are likely to be pressured by higher costs associated with production and supply.
In the second quarter of 2019, Tilray beat revenue estimates with a 371% year-over-year increase in the topline to $45.9 million. Net loss widened to $0.32 per share.
Tilray’s shares have fallen 68% year-to-date and 81% over the past 12 months.
Most Popular
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company
Walgreens Boots Alliance set to report earnings next week. Here’s what to expect
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the drug store chain that is expanding into a diversified healthcare provider, is on a restructuring drive aimed at better aligning the business with